

**S0805 – A Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without allogeneic stem cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)**

**Submission checklist for S0805 TBI Radiation Oncology Quality Assurance Materials**

Patient: \_\_\_\_\_

Registration# \_\_\_\_\_

Data can be submitted via email to the following address: [datasubmission@garc.org](mailto:datasubmission@garc.org). If data is sent via courier please send material to:

IROC RI (QARC)  
Building B, Suite 201  
640 George Washington Highway  
Lincoln, RI 02865-4207

Treating Radiation Oncologist:

Name: \_\_\_\_\_

E-mail: \_\_\_\_\_

TBI Review materials to be submitted are detailed below:

DATE  
SUBMITTED

\_\_\_\_\_ QARC TBI Summary form (available at [www.garc.org](http://www.garc.org))

**(completed form must include reference point dose data)**

\_\_\_\_\_ RT Daily Treatment Record including prescription, daily and cumulative doses

\_\_\_\_\_ Copy of this Checklist for Submission of Radiation Oncology Quality Assurance Materials.

(also available at [www.garc.org](http://www.garc.org))

**Please enclose a copy of this Checklist together with the RT materials you submit. All materials must be labeled with the assigned protocol and registration number.**

Please contact us by calling Tel: (401) 753-7600 or email at [swog@garc.org](mailto:swog@garc.org) for clarification as necessary. Thank you for your ongoing co-operation.